Using an independent cutoff of 6.9, nearly all patients in the GFAP‐astrocytopathy group (97%) exhibited a positive λ‐FLC index, while only 56% of patients with MS did (Table 2). This evidence concerns the gene GFAP and myeloid sarcoma.